Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development

Vaccine

Volumn 35, Issue 3, 2017, Pages 461-468

  Melero, José A ^a   Mas, Vicente ^a   McLellan, Jason S ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

RSV glycoproteins and vaccine development

Indexed keywords

CELL SURFACE RECEPTOR; RESPIRATORY SYNCYTIAL VIRUS GLYCOPROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; GLYCOPROTEIN; VIRUS ANTIGEN;

ANTIGENICITY; ARTICLE; CONFORMATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOBIOLOGY; IMMUNOGENICITY; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; CHEMISTRY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION; VIRUS ENTRY;

ANTIGENS, VIRAL; GLYCOPROTEINS; HUMANS; PROTEIN CONFORMATION; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRUS INTERNALIZATION;

EID: 85006355019     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.09.045     Document Type: Article

References (94)

1. [1] Afonso, C.L., Amarasinghe, G.K., Banyai, K., et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol 161:8 (2016), 2351–2360.
2. [2] Collins, P.L., Melero, J.A., Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162:1–2 (2011), 80–99.
3. [3] Levine, S., Klaiber-Franco, R., Paradiso, P.R., Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol 68:Pt 9 (1987), 2521–2524.
4. [4] Walsh, E.E., Hruska, J., Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol 47:1 (1983), 171–177.
5. [5] Perez, M., Garcia-Barreno, B., Melero, J.A., Carrasco, L., Guinea, R., Membrane permeability changes induced in Escherichia coli by the SH protein of human respiratory syncytial virus. Virology 235:2 (1997), 342–351.
6. [6] Gan, S.W., Tan, E., Lin, X., et al. The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J Biol Chem 287:29 (2012), 24671–24689.
7. [7] Hall, C.B., Walsh, E.E., Long, C.E., Schnabel, K.C., Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163:4 (1991), 693–698.
8. [8] Glezen, W.P., Taber, L.H., Frank, A.L., Kasel, J.A., Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140:6 (1986), 543–546.
9. [9] Falsey, A.R., Walsh, E.E., Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 177:2 (1998), 463–466.
10. [10] Graham, B.S., Anderson, L.J., Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 372 (2013), 391–404.
11. [11] Wertz, G.W., Collins, P.L., Huang, Y., Gruber, C., Levine, S., Ball, L.A., Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci USA 82:12 (1985), 4075–4079.
12. [12] Collins, P.L., Mottet, G., Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A. J Gen Virol 73:Pt 4 (1992), 849–863.
13. [13] Garcia-Beato, R., Martinez, I., Franci, C., Real, F.X., Garcia-Barreno, B., Melero, J.A., Host cell effect upon glycosylation and antigenicity of human respiratory syncytial virus G glycoprotein. Virology 221:2 (1996), 301–309.
14. [14] Kwilas, S., Liesman, R.M., Zhang, L., Walsh, E., Pickles, R.J., Peeples, M.E., Respiratory syncytial virus grown in vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans. J Virol 83:20 (2009), 10710–10718.
15. [15] Johnson, P.R., Spriggs, M.K., Olmsted, R.A., Collins, P.L., The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA 84:16 (1987), 5625–5629.
16. [16] Melero, J.A., Moore, M.L., Influence of respiratory syncytial virus strain differences on pathogenesis and immunity. Curr Top Microbiol Immunol 372 (2013), 59–82.
17. [17] Hansen, J.E., Lund, O., Tolstrup, N., Gooley, A.A., Williams, K.L., Brunak, S., NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj J 15:2 (1998), 115–130.
18. [18] Cane, P.A., Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 11:2 (2001), 103–116.
19. [19] Anderson, L.J., Hierholzer, J.C., Tsou, C., et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 151:4 (1985), 623–633.
20. [20] Mufson, M.A., Orvell, C., Rafnar, B., Norrby, E., Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 66:Pt 10 (1985), 2111–2124.
21. [21] Houspie, L., Lemey, P., Keyaerts, E., et al. Circulation of HRSV in Belgium: from multiple genotype circulation to prolonged circulation of predominant genotypes. PLoS ONE, 8(4), 2013, e60416.
22. [22] Langedijk, J.P., Schaaper, W.M., Meloen, R.H., van Oirschot, J.T., Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus. J Gen Virol 77:Pt 6 (1996), 1249–1257.
23. [23] Langedijk, J.P., de Groot, B.L., Berendsen, H.J., van Oirschot, J.T., Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology 243:2 (1998), 293–302.
24. [24] van den Hoogen, B.G., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Analysis of the genomic sequence of a human metapneumovirus. Virology 295:1 (2002), 119–132.
25. [25] van den Hoogen, B.G., Herfst, S., Sprong, L., et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 10:4 (2004), 658–666.
26. [26] Leyrat, C., Paesen, G.C., Charleston, J., Renner, M., Grimes, J.M., Structural insights into the human metapneumovirus Glycoprotein ectodomain. J Virol, 2014.
27. [27] Tripp, R.A., Jones, L.P., Haynes, L.M., Zheng, H., Murphy, P.M., Anderson, L.J., CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2:8 (2001), 732–738.
28. [28] Johnson, S.M., McNally, B.A., Ioannidis, I., et al. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog, 11(12), 2015, e1005318.
29. [29] Jeong, K.I., Piepenhagen, P.A., Kishko, M., et al. CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner. PLoS ONE, 10(6), 2015, e0130517.
30. [30] Chirkova, T., Lin, S., Oomens, A.G., et al. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol 96:9 (2015), 2543–2556.
31. [31] Hallak, L.K., Spillmann, D., Collins, P.L., Peeples, M.E., Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol 74:22 (2000), 10508–10513.
32. [32] Hallak, L.K., Collins, P.L., Knudson, W., Peeples, M.E., Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271:2 (2000), 264–275.
33. [33] Martinez, I., Melero, J.A., Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J Gen Virol 81:Pt 11 (2000), 2715–2722.
34. [34] Techaarpornkul, S., Collins, P.L., Peeples, M.E., Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 294:2 (2002), 296–304.
35. [35] Feldman, S.A., Hendry, R.M., Beeler, J.A., Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 73:8 (1999), 6610–6617.
36. [36] Hendricks, D.A., McIntosh, K., Patterson, J.L., Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol 62:7 (1988), 2228–2233.
37. [37] Roberts, S.R., Lichtenstein, D., Ball, L.A., Wertz, G.W., The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons. J Virol 68:7 (1994), 4538–4546.
38. [38] Escribano-Romero, E., Rawling, J., Garcia-Barreno, B., Melero, J.A., The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans. J Virol 78:7 (2004), 3524–3532.
39. [39] Bukreyev, A., Yang, L., Fricke, J., et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82:24 (2008), 12191–12204.
40. [40] Martinez, I., Dopazo, J., Melero, J.A., Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78:Pt 10 (1997), 2419–2429.
41. [41] Anderson, L.J., Bingham, P., Hierholzer, J.C., Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 62:11 (1988), 4232–4238.
42. [42] Walsh, E.E., Hall, C.B., Schlesinger, J.J., Brandriss, M.W., Hildreth, S., Paradiso, P., Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J Gen Virol 70:Pt 11 (1989), 2953–2961.
43. [43] Martinez, I., Melero, J.A., Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J Gen Virol 79:Pt 9 (1998), 2215–2220.
44. [44] Radu, G.U., Caidi, H., Miao, C., Tripp, R.A., Anderson, L.J., Haynes, L.M., Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J Virol 84:18 (2010), 9632–9636.
45. [45] Boyoglu-Barnum, S., Gaston, K.A., Todd, S.O., et al. A respiratory syncytial virus (RSV) anti-G protein F(ab′)2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol 87:20 (2013), 10955–10967.
46. [46] Zhang, W., Choi, Y., Haynes, L.M., et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 84:2 (2010), 1148–1157.
47. [47] Lee, Y.N., Hwang, H.S., Kim, M.C., et al. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology 476 (2015), 217–225.
48. [48] Jorquera, P.A., Choi, Y., Oakley, K.E., et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS ONE, 8(9), 2013, e74905.
49. [49] Power, U.F., Plotnicky-Gilquin, H., Huss, T., et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230:2 (1997), 155–166.
50. [50] Gonzalez-Reyes, L., Ruiz-Arguello, M.B., Garcia-Barreno, B., et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 98:17 (2001), 9859–9864.
51. [51] Begona Ruiz-Arguello, M., Gonzalez-Reyes, L., Calder, L.J., et al. Effect of proteolytic processing at two distinct sites on shape and aggregation of an anchorless fusion protein of human respiratory syncytial virus and fate of the intervening segment. Virology 298:2 (2002), 317–326.
52. [52] Karron, R.A., Buonagurio, D.A., Georgiu, A.F., et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA 94:25 (1997), 13961–13966.
53. [53] Techaarpornkul, S., Barretto, N., Peeples, M.E., Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 75:15 (2001), 6825–6834.
54. [54] Murphy, B.R., Collins, P.L., Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 110:1 (2002), 21–27.
55. [55] Crim, R.L., Audet, S.A., Feldman, S.A., Mostowski, H.S., Beeler, J.A., Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J Virol 81:1 (2007), 261–271.
56. [56] Tayyari, F., Marchant, D., Moraes, T.J., Duan, W., Mastrangelo, P., Hegele, R.G., Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 17:9 (2011), 1132–1135.
57. [57] Rawling, J., Garcia-Barreno, B., Melero, J.A., Insertion of the two cleavage sites of the respiratory syncytial virus fusion protein in Sendai virus fusion protein leads to enhanced cell-cell fusion and a decreased dependency on the HN attachment protein for activity. J Virol 82:12 (2008), 5986–5998.
58. [58] Rawling, J., Cano, O., Garcin, D., Kolakofsky, D., Melero, J.A., Recombinant Sendai viruses expressing fusion proteins with two furin cleavage sites mimic the syncytial and receptor-independent infection properties of respiratory syncytial virus. J Virol 85:6 (2011), 2771–2780.
59. [59] Swanson, K.A., Settembre, E.C., Shaw, C.A., et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 108:23 (2011), 9619–9624.
60. [60] McLellan, J.S., Yang, Y., Graham, B.S., Kwong, P.D., Structure of the respiratory syncytial virus fusion glycoprotein in the post-fusion conformation reveals preservation of neutralizing epitopes. J Virol 85:15 (2011), 7788–7796.
61. [61] McLellan, J.S., Chen, M., Leung, S., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:6136 (2013), 1113–1117.
62. [62] McLellan, J.S., Chen, M., Joyce, M.G., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:6158 (2013), 592–598.
63. [63] Calder, L.J., Gonzalez-Reyes, L., Garcia-Barreno, B., et al. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271:1 (2000), 122–131.
64. [64] Martin, D., Calder, L.J., Garcia-Barreno, B., Skehel, J.J., Melero, J.A., Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity. J Gen Virol 87:Pt 6 (2006), 1649–1658.
65. [65] Yin, H.S., Wen, X., Paterson, R.G., Lamb, R.A., Jardetzky, T.S., Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:7072 (2006), 38–44.
66. [66] Krarup, A., Truan, D., Furmanova-Hollenstein, P., et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun, 6, 2015, 8143.
67. [67] Yin, H.S., Paterson, R.G., Wen, X., Lamb, R.A., Jardetzky, T.S., Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci USA 102:26 (2005), 9288–9293.
68. [68] Welch, B.D., Liu, Y., Kors, C.A., Leser, G.P., Jardetzky, T.S., Lamb, R.A., Structure of the cleavage-activated prefusion form of the parainfluenza virus 5 fusion protein. Proc Natl Acad Sci USA 109:41 (2012), 16672–16677.
69. [69] Beeler, J.A., Van Wyke, C.K., Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63:7 (1989), 2941–2950.
70. [70] Garcia-Barreno, B., Palomo, C., Penas, C., Delgado, T., Perez-Brena, P., Melero, J.A., Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 63:2 (1989), 925–932.
71. [71] Arbiza, J., Taylor, G., Lopez, J.A., et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 73:Pt 9 (1992), 2225–2234.
72. [72] Lopez, J.A., Bustos, R., Orvell, C., et al. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 72:8 (1998), 6922–6928.
73. [73] Lounsbach, G.R., Bourgeois, C., West, W.H., Robinson, J.W., Carter, M.J., Toms, G.L., Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli. J Gen Virol 74:Pt 12 (1993), 2559–2565.
74. [74] Langedijk, J.P., Meloen, R.H., van Oirschot, J.T., Identification of a conserved neutralization site in the first heptad repeat of the fusion protein of respiratory syncytial virus. Arch Virol 143:2 (1998), 313–320.
75. [75] Sastre, P., Melero, J.A., Garcia-Barreno, B., Palomo, C., Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. J Med Virol 76:2 (2005), 248–255.
76. [76] Magro, M., Mas, V., Chappell, K., et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci USA 109:8 (2012), 3089–3094.
77. [77] Kwakkenbos, M.J., Diehl, S.A., Yasuda, E., et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 16:1 (2010), 123–128.
78. [78] Gilman, M.S., Moin, S.M., Mas, V., et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog, 11(7), 2015, e1005035.
79. [79] Corti, D., Bianchi, S., Vanzetta, F., et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501:7467 (2013), 439–443.
80. [80] Schuster, J.E., Cox, R.G., Hastings, A.K., et al. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis, 2014.
81. [81] Magro, M., Andreu, D., Gomez-Puertas, P., Melero, J.A., Palomo, C., Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol 84:16 (2010), 7970–7982.
82. [82] Ngwuta, J.O., Chen, M., Modjarrad, K., et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med, 7(309), 2015, 309ra162.
83. [83] Swanson, K.A., Balabanis, K., Xie, Y., et al. A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes. J Virol 88:20 (2014), 11802–11810.
84. [84] Palomo, C., Mas, V., Thom, M., et al. Influence of respiratory syncytial virus F glycoprotein conformation on induction of protective immune responses. J Virol 90:11 (2016), 5485–5498.
85. [85] Smith, G., Raghunandan, R., Wu, Y., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE, 7(11), 2012, e50852.
86. [86] Liang, B., Surman, S., Amaro-Carambot, E., et al. Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate. J Virol 89:18 (2015), 9499–9510.
87. [87] McGinnes, C.L., Schmidt, M.R., Kenward, S.A., Woodland, R.T., Morrison, T.G., Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein. J Virol 89:13 (2015), 6835–6847.
88. [88] Cullen, L.M., Blanco, J.C., Morrison, T.G., Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med, 13, 2015, 350.
89. [89] McLellan, J.S., Correia, B.E., Chen, M., et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol, 27, 2011.
90. [90] Correia, B.E., Bates, J.T., Loomis, R.J., et al. Proof of principle for epitope-focused vaccine design. Nature 507:7491 (2014), 201–206.
91. [91] Nair, H., Nokes, D.J., Gessner, B.D., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:9725 (2010), 1545–1555.
92. [92] Lozano, R., Naghavi, M., Foreman, K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:9859 (2012), 2095–2128.
93. [93] Jentoft, N., Why are proteins O-glycosylated?. Trends Biochem Sci 15:8 (1990), 291–294.
94. [94] Garcia-Beato, R., Melero, J.A., The C-terminal third of human respiratory syncytial virus attachment (G) protein is partially resistant to protease digestion and is glycosylated in a cell-type-specific manner. J Gen Virol 81:Pt 4 (2000), 919–927.